ea0035p486 | Diabetes therapy | ECE2014
Tigas Stelios
, Tsartsarakis Antonios
, Efthimiou Patricia
, Ligkros Nikos
, Gaitanis Georgios
, Tsatsoulis Agathocles
, Bassukas Ioannis
Aim: Recent reports of adverse skin reactions in patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors have increased awareness towards skin-targeting side effects. Bullous pemphigoid (BP) is an autoimmune blistering dermatosis with significant morbidity and mortality. We report the development of BP in patients with type 2 diabetes mellitus (T2DM) treated with DPP-4 inhibitors.Method: Evaluation of the temporal distribution of the frequency of BP...